A retrospective analysis demonstrated that immune checkpoint inhibitors provide variable benefit for KRAS-mutant NSCLC, with the KRAS plus STK11/LKB1 co-mutation (KL subtype) being resistant to this treatment class (7). Here, KRAS is linked to non-small cell lung carcinoma.